Protagonist Therapeutics
PTGX
PTGX
240 hedge funds and large institutions have $2.44B invested in Protagonist Therapeutics in 2024 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 91 increasing their positions, 75 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
0% more funds holding
Funds holding: 239 → 240 (+1)
8% less call options, than puts
Call options by funds: $8.73M | Put options by funds: $9.52M
12% less capital invested
Capital invested by funds: $2.78B → $2.44B (-$337M)
Holders
240
Holding in Top 10
7
Calls
$8.73M
Puts
$9.52M
Top Buyers
| 1 | +$38.6M | |
| 2 | +$35.1M | |
| 3 | +$13.6M | |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$13.2M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$11.2M |
Top Sellers
| 1 | -$54M | |
| 2 | -$13.1M | |
| 3 | -$12.6M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$11.4M |
| 5 |
CC
Checkpoint Capital
San Francisco,
California
|
-$10.8M |